New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations ...
The humanized monoclonal anti-CD20 antibody, rituximab, has shown promise to treat follicular lymphoma—when used as a single agent, and also when used in combination with chemotherapy.
In the era of rituximab, whether ASCT is needed in the treatment of follicular lymphoma remains a valid question. In the retrospective GELA study, both rituximab and ASCT had a benefit on patients ...
There is no standard therapeutic regimen for patients with relapsed or refractory FL. Many options exist, and factors to consider include knowledge of previous therapies and their efficacy ...
Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...
So we're going to talk about the late-breaker abstract to be presented, looking at tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma. Dr. Sawalha, do you want ...
SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to ...
What’s the next step for this patient with a 4-year history of low-grade follicular lymphoma and who now ... with 6 cycles of bendamustine and rituximab (BR), and has been monitored clinically ...
Hosted on MSN1mon
Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphomaFor the follicular lymphoma trial, patients receiving loncastuximab and rituximab had a 67% complete response rate, meaning their cancer could no longer be detected by imaging, and an overall ...
lenalidomide and rituximab in patients with advanced follicular lymphoma. Caimi explained that the findings showed that “1 year of the triplet combination seems to be better than the doublet in ...
Branded as Rituxan Hycela, subcutaneous rituximab is administered in combination with hyaluronidase human and is approved for adults with follicular lymphoma, diffuse large B-cell lymphoma and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results